IntrinsicIntrinsic
← All summaries

Akso Health Group

AHG
Financials & Chart →

Business Summary

Akso Health Group operates primarily in the "Internet + healthcare" industry in China, with a strategic focus on online hospital services, chain pharmacies, and the sale of medical devices. The company is also developing cancer therapy and radiation oncology centers in the U.S. and provides marketing promotion services to the car insurance broker industry in China. The company has transitioned from its historical P2P marketplace and online microlending businesses, which were fully disposed of by December 2020 and ceased new loan issuance by May 2019, respectively . The company's current corporate structure involves unique risks due to its holding company status in the Cayman Islands and primary operations in China, subjecting it to PRC laws and regulations, including those related to foreign investment, data security, and cybersecurity .

The company's core business model revolves around generating revenue through direct sales of pharmaceutical products and medical supplies, medical service fees from online hospital diagnostic and treatment offerings, collaborative profit-sharing with insurance partners, and technical and brand collaborations for program development and marketing services. Revenue from direct sales of pharmaceutical products and medical supplies is recognized on a gross basis as the company takes inventory risk . Medical and clinical service revenue is also recognized on a gross basis, as the company supervises, evaluates, manages, and compensates medical staff and has discretion in pricing . Commission revenue from insurance sales is recognized on a net basis, as the company acts as an agency . Fees collected through its medical consultation app are accounted for using the gross method, as the company controls pricing and has minimum purchase commitments with pharmacies and minimum payouts to doctors .

The company's product and service lines include the sale of medical devices, online healthcare services, and marketing promotion services. In the fiscal year ended March 31, 2025, revenue attributable to the sales of medical equipment was $0.4 million, representing 2.8% of total revenue . This segment involves selling Class II medical devices like anesthesia laryngoscopes and Class III medical devices like defibrillators in China through Qingdao Akso, and previously included COVID-19 Rapid Antigen test kits in the U.S. through Akso Online MediTech, which ceased sales at the end of 2022 , . The online healthcare services business, initiated through the acquisition of Tianjin Wangyi Cloud Co., Ltd. in November 2024, provides health consultancy and online sales of medicines and health products through its subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd. . The marketing promotion services business, also acquired with Tianjin Wangyi Cloud Co., Ltd., provides potential car insurance purchaser information to insurance broker agencies, earning commissions on successful recommendations .

For the fiscal year ended March 31, 2025, Akso Health Group reported net revenues of $14,777,798 . The cost of goods sold for the same period was $15,059,324 , resulting in a gross loss of $(281,526) . Total operating expenses amounted to $166,022,826 , which included $3,641,446 in general and administrative expenses and a significant impairment of goodwill and intangible assets totaling $162,381,380 . The company reported a loss from continuing operations of $(166,304,352) , and after accounting for total other income (loss), net of $34,073 and a benefit for income tax of $(30,801,146) , the net loss from continuing operations was $(135,469,133) . Net loss from discontinued operations was nil for the fiscal year ended March 31, 2025 .

Comparing fiscal year 2025 to 2024, net revenues increased significantly from $2,414,338 to $14,777,798 , primarily driven by the introduction of marketing promotion service revenue, which contributed $14,366,602 in 2025, compared to nil in 2024 . Conversely, revenue from the sale of medical devices decreased substantially from $2,416,797 in 2024 to $415,020 in 2025. The company's gross profit shifted from a positive $122,132 in 2024 to a gross loss of $(281,526) in 2025. Operating expenses saw a dramatic increase from $8,760,172 in 2024 to $166,022,826 in 2025, largely due to the $162,381,380 impairment of goodwill and intangible assets in 2025. This led to a substantial increase in net loss from continuing operations, from $(9,116,779) in 2024 to $(135,469,133) in 2025.

During the reported period, Akso Health Group completed the acquisition of Tianjin Wangyi Cloud Co., Ltd. in November 2024, gaining 100% equity interest by December 10, 2024, which brought in online hospital services and marketing promotion services . The company also established Akso Medical Cloud Limited in the British Virgin Islands on November 15, 2023, and Akso Medi-care Limited in Hong Kong on December 4, 2023, followed by Tianjin Akso Enterprise Management Co., Ltd. in China on January 16, 2024, to support its healthcare expansion . Earlier, in May 2023, the company disposed of its social e-commerce business .

Business Outlook

Akso Health Group is strategically focused on expanding its presence in the online hospital and chain pharmacies segments in China, while also developing cancer therapy and radiation oncology centers in the U.S. The company plans to acquire multiple independent pharmacies nationwide in China, integrating them into a chain using its offline resources and IT solutions to enhance competitiveness . In the U.S., the company intends to open 2 vaccine research centers for AIDS and Covid-19 and 100 radiation oncology centers on the east coast, providing radiotherapy, personalized consultation, and conventional treatment planning for cancer patients .

The company's growth strategies include digital presence enhancement through optimizing online platforms and targeted social media, community engagement via partnerships with local health service centers, and talent development to strengthen team capabilities . The revenue model for its online healthcare services will include direct sales through its online health product marketplace, medical service fees from Tianjin Deyihui Online Hospital's diagnostic and treatment offerings, collaborative profit-sharing with insurance partners, and technical and brand collaborations for program development and marketing services .

Research and development efforts are concentrated on developing AI-driven health management solutions and leveraging big data analytics to enhance digital health platforms, which is integral to maintaining leadership in smart healthcare innovation . The sales strategy encompasses a multi-channel approach, combining online health platforms with offline distribution networks, with a goal to maximize market reach by optimizing supply chain processes and forging strategic partnerships . The company's current focus is on integrating digital health services with existing medical supply chains to streamline distribution and service delivery .

The company's growth plan for new cancer therapy and radiation oncology centers could result in fluctuations in short-term financial performance, as newly opened centers generally have lower income and higher operating costs during initial stages and may take years to achieve monthly breakeven and longer to recover initial investment . The implementation process for building these centers on the east coast of the United States will be complex, time-consuming, and subject to uncertainty, including identifying suitable markets, acquiring government approvals, and controlling planned investments .

Risk Factors

Akso Health Group faces significant risks across macroeconomic, competitive, regulatory, geopolitical, and operational dimensions. Macroeconomic and geopolitical risks include the potential for deterioration in China-U.S. relations, which could adversely affect business, offering, and listing status due to trade restrictions, sanctions, or negative public perception . Regulatory risks are substantial, particularly in China, where the government exerts significant oversight and discretion over business operations, with laws and regulations that are often vague, uncertain, and subject to rapid change, potentially leading to fines, penalties, or operational disruptions . The company is subject to various data security and privacy laws in both China and the U.S., including the PRC Cybersecurity Law, Data Security Law, and Personal Information Protection Law, as well as HIPAA and CCPA in the U.S., with non-compliance potentially resulting in significant penalties, legal liabilities, and reputational harm . Operational risks include dependence on a concentrated client base in its marketing promotion services, where four clients accounted for 19.9%, 17.7%, 15.6%, and 10.1% of total revenue for the year ended March 31, 2025 , and two clients accounted for 76.9% and 16.5% of total accounts receivable . The company also relies on a single significant supplier, Brand Meditech (Asia) Company Limited, for 100.0% of its medical device purchases for the fiscal year ended March 31, 2025 , and one supplier accounts for approximately 94.5% of total purchase costs related to marketing promotion service and 92.0% of total costs of revenue for the year ended March 31, 2025 , exposing it to supply chain disruptions. Furthermore, the company does not carry business interruption insurance or medical malpractice insurance for its online healthcare services , which could lead to substantial costs and liabilities in the event of unforeseen events or claims.

Management Priorities

Management's message emphasizes a strategic pivot towards the "Internet + healthcare" sector, following the disposition of its P2P marketplace and social e-commerce businesses. The company is actively pursuing growth through the acquisition of online hospital services and chain pharmacies in China, as evidenced by the recent acquisition of Tianjin Wangyi Cloud Co., Ltd. in November 2024, which now provides online hospital services and marketing promotion services . A key strategic priority is the development of cancer therapy and radiation oncology centers in the U.S., with plans to open 2 vaccine research centers for AIDS and Covid-19 and 100 radiation oncology centers on the east coast . Management also highlights the importance of integrating medical products, telemedicine, and offline treatment platforms into a comprehensive healthcare information service system, with a focus on AI-driven health management solutions and big data analytics . The company's overall tone suggests a commitment to disciplined capital allocation and investor accountability, particularly in evaluating future acquisitions of internet hospitals/clinics based on real-time policy and market dynamics .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 4, Information on the Company — A. History and Development of the Company
  2. [2] Item 3, Key Information — Permissions Required from the PRC Authorities for the Operations and Securities Offerings of PRC Subsidiaries and Consolidated Affiliated Entities
  3. [3] Item 4, Information on the Company — B. Business Overview — Revenue Model
  4. [4] Item 4, Information on the Company — B. Business Overview — Revenue Model
  5. [5] Item 4, Information on the Company — B. Business Overview — Revenue Model
  6. [6] Item 4, Information on the Company — B. Business Overview — Revenue Model
  7. [7] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Revenues
  8. [8] Item 4, Information on the Company — B. Business Overview — Sales of medical devices
  9. [9] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Sale of medical devices
  10. [10] Item 4, Information on the Company — B. Business Overview — Online Healthcare Services Business
  11. [11] Item 4, Information on the Company — B. Business Overview — Marketing Promotion Services
  12. [12] Item 5, Operating and Financial Review and Prospects — A. Operating Results — NET REVENUES
  13. [13] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Cost of goods sold
  14. [14] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Gross Profit
  15. [15] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Total operating expenses
  16. [16] Item 5, Operating and Financial Review and Prospects — A. Operating Results — General and administrative expenses
  17. [17] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Impairment of goodwill and intangible assets
  18. [18] Item 5, Operating and Financial Review and Prospects — A. Operating Results — LOSS FROM CONTINUING OPERATIONS
  19. [19] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Total other income (loss), net
  20. [20] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Provision (benefit) for income tax
  21. [21] Item 5, Operating and Financial Review and Prospects — A. Operating Results — NET LOSS FROM CONTINUING OPERATIONS
  22. [22] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Discontinued Operations
  23. [23] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Net Revenues
  24. [24] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Net Revenues
  25. [25] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Revenues
  26. [26] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Revenues
  27. [27] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Revenues
  28. [28] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Revenues
  29. [29] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Gross Profit
  30. [30] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Gross Profit
  31. [31] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Total operating expenses
  32. [32] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Total operating expenses
  33. [33] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Impairment of goodwill and intangible assets
  34. [34] Item 5, Operating and Financial Review and Prospects — A. Operating Results — NET LOSS FROM CONTINUING OPERATIONS
  35. [35] Item 5, Operating and Financial Review and Prospects — A. Operating Results — NET LOSS FROM CONTINUING OPERATIONS
  36. [36] Item 4, Information on the Company — A. History and Development of the Company
  37. [37] Item 4, Information on the Company — A. History and Development of the Company
  38. [38] Item 4, Information on the Company — A. History and Development of the Company
  39. [39] Item 4, Information on the Company — B. Business Overview
  40. [40] Item 4, Information on the Company — B. Business Overview — Akso Health’s radiation oncology services business
  41. [41] Item 4, Information on the Company — B. Business Overview — Growth Strategies/Marketing and Sales Strategy
  42. [42] Item 4, Information on the Company — B. Business Overview — Revenue Model
  43. [43] Item 4, Information on the Company — B. Business Overview — Research and Development
  44. [44] Item 4, Information on the Company — B. Business Overview — Sales and Distribution
  45. [45] Item 4, Information on the Company — B. Business Overview — Integration of Digital Health Services
  46. [46] Item 3, Key Information — D. Risk Factors — Our development of new cancer therapy and radiation oncology centers could result in fluctuations in our short-term financial performance, and newly opened cancer therapy and radiation oncology centers and clinics may not achieve timely profitability, or at all.
  47. [47] Item 3, Key Information — D. Risk Factors — Our growth plan includes the construction of cancer therapy and radiation oncology centers. If we cannot identify and seize growth opportunities in fast-changing markets, our future growth will face uncertainties.
  48. [48] Item 3, Key Information — D. Risk Factors — Our business, financial performance and results of operations could be adversely affected by deterioration of the relation between China and the United States.
  49. [49] Item 3, Key Information — D. Risk Factors — There are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly decline or become worthless.
  50. [50] Item 3, Key Information — D. Risk Factors — In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on NASDAQ, financial condition, and results of operations.
  51. [51] Item 4, Information on the Company — B. Business Overview — Our Customers
  52. [52] Item 4, Information on the Company — B. Business Overview — Our Customers
  53. [53] Item 4, Information on the Company — B. Business Overview — Our Suppliers
  54. [54] Item 4, Information on the Company — B. Business Overview — Our Suppliers
  55. [55] Item 3, Key Information — D. Risk Factors — We do not have business insurance coverage.
  56. [56] Item 3, Key Information — D. Risk Factors — We may become subject to medical liability claims in connection with our online healthcare services, which could cause us to incur significant expenses and be liable for significant damages if any claim is not covered by insurance.
  57. [57] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Overview
  58. [58] Item 4, Information on the Company — B. Business Overview — Akso Health’s radiation oncology services business
  59. [59] Item 4, Information on the Company — B. Business Overview — Integration of Digital Health Services
  60. [60] Item 5, Operating and Financial Review and Prospects — A. Operating Results — Overview

Analysis on 5/22/2026